Abnormal movement in US stocks | Q1 profit turns into loss, Sarepta Therapeutics (SRPT.US) continues to fall by nearly 20%, a 40% decrease in 2 trading days

According to the Wisdom Financial APP, on Wednesday, Sarepta Therapeutics (SRPT.US) continued to fall by nearly 20%, with a 40% decline over the past two trading days, closing at $37.27. On the news front, the company reported a non-GAAP diluted loss of $3.42 per share for the first quarter, compared to a profit of $0.72 per share in the same period last year. Analysts surveyed by FactSet had expected a profit of $2.52 per share. Revenue increased from approximately $414 million in the same period last year to $745 million, compared to analysts' expectations of $688 million. The company revised its net product revenue guidance for 2025 down to a range of $2.3 billion to $2.6 billion.